Connected recovery infrastructure, starting with stroke
Turn home rehabilitation into a visible, connected pathway.
REGAIN connects the programme prescribed by a clinician with the person doing the work, the people supporting them and the evidence needed to improve what happens next.
- Origin
- Research-led
- Design
- Lived experience
- Intelligence
- FASTlab architecture
Research foundationUniversity of Newcastle · HMRI · ARC Connected Sensors for Health
TodayBall roll completedConfidence · steady
Care circleSupport connectedWith permission
Clinician viewReview by exceptionHuman judgement retained
Stroke population: Australian Commission on Safety and Quality in Health Care, June 2026. Capital range is a planning scenario subject to final scope and quotation.
The opportunity
A rehabilitation workflow—not another exercise library.
REGAIN is being designed as the connective layer between clinical intent and recovery at home: accessible practice, structured reflection, appropriate support and evidence that can inform the next human decision.
Executive summary
The missing layer after discharge.
Home rehabilitation is where repetition, confidence and everyday support matter most—yet it is also where the pathway becomes hardest to see. REGAIN aims to make that work easier to follow and more useful to everyone around recovery.
Where the pathway goes dark
Conceptual illustration, not measured dataThe programme travels. The pathway does not.
Instructions, videos, appointments and family support often sit apart rather than operating as one coherent experience.
What happens at home is difficult to understand.
Attendance alone cannot explain confidence, fatigue, pain, difficulty or the context surrounding participation.
Care circles are important but poorly equipped.
Family and friends need a useful role that supports recovery without shifting clinical responsibility onto them.
Investment thesis
Build the connective workflow, prove value in stroke, then license the pathway.
- Clear wedge
- Clinician-prescribed rehabilitation activated for use at home.
- Multi-sided value
- A simpler experience for survivors; bounded support for carers; structured visibility for services.
- Expandable architecture
- Potential pathway profiles for frailty, falls, orthopaedic and neurological recovery after validation.
- Compounding asset
- Governed evidence about what works, for whom, in what context and with what confidence.
Platform
One loop around the person recovering.
The proposed MVP connects five actions without attempting to automate care.
The person recoveringComposite characterSurvivorPractise
Accessible guided activities.
9:41●●●
Week 3 · MargaretMy recovery
New from your clinician
Your home programme is ready
Set by your physiotherapist for this week.
Ball rollArm and hand
Sit to standStrength
Reach and placeArm and hand
Weekly check-in2 minutes
Getting started
Scan the code from your clinic
No email neededA carer can helpLarge controls
Ball roll
Captions onVoice guidance
Start activity
Weekly check-in
How did this week feel?
Confidence
Fatigue
Pain
Difficulty
Share with my clinician
Updated this week
Your programme has changed
Your physiotherapist reviewed your check-in and adjusted next week's activities.
Ball rollKept
Sit to standFewer repetitions
Rest breaksAdded
Clinician viewReview by exception
Patient AWeek 5Steady
MargaretWeek 3Review
Patient CWeek 2Steady
Human judgement retained. Signals prompt a review; the clinician decides.
Designed around real life
“I just want to get back to my Tuesday craft group.”Meet Margaret · composite character, illustrative scenario
Accessible home practice
Guidance without friction
Large controls, captions, voice support, carer-assisted onboarding and pathways that do not assume an email address.
Product boundary
REGAIN is currently conceived as a rehabilitation resource companion. It is not a medical device, does not diagnose or direct treatment and does not replace clinical care.
Market
A large need. A deliberately narrow entry point.
More than 440,000 Australians live with the effects of stroke. REGAIN’s initial commercial focus is not every survivor: it is the organisations responsible for extending rehabilitation into the home.
TAM signal440,000+Australians living with the effects of stroke
Demonstrates the scale of persistent need; it is not presented as obtainable revenue.
Service marketRehabilitation providersPublic, private and community pathways
Organisations with a defined cohort, clinical workflow and need for visibility beyond appointments.
Beachhead2–3 pilot sitesA focused validation cohort
The first commercial objective: paid, evidence-generating deployments—not premature national scale.
Commercial model
Organisation-funded access is the leading hypothesis.
The pilot will test who buys, what they value and which unit of pricing best matches procurement. The figures below are commercial scenarios, not contracted prices or forecasts.
Provider licence
A service deploys REGAIN to a defined cohort and pays for the platform, onboarding and evidence reporting.
- Activation or cohort-based access
- Implementation support
- Evidence and value reporting
- Annual renewal pathway
Illustrative year-one site$172,500
Model—not a forecast
Platform access$125,000
Implementation$25,000
Evidence reporting$22,500
Sensitivity across the working rangesSite total, $k · select a cell
Indicative commercial test per site.
Working hypothesis per active patient annually.
Validation and moat
The product improves by making reasoning visible.
REGAIN sits as an application profile within FASTlab’s Evidence Intelligence stack. The architecture governs how activity becomes meaning, how confidence is expressed and how learning is retained.
The defensible layer
Most platforms collect data. REGAIN is designed to govern what happens next.
FASTlab Evidence Intelligence Architecture™ Stage 1 of 7
Start with the decision
Define what must be understood before deciding what data is relevant.
In REGAIN, illustratively
Refine the POC
Complete workflows and accessibility design.
Output: testable experienceStakeholder testing
Test with survivors, carers and clinicians.
Output: usability evidenceStructured pilot
Test engagement, workflow and buyer value.
Output: adoption evidenceFirst paid deployment
Convert learning into a repeatable offer.
Output: revenue evidenceInvestment ask
Capital tied to evidence-producing milestones.
The immediate objective is to finish the product definition, secure a precise build pathway and fund validation toward first revenue. The final raise structure follows the completed POC and development quotation.
Software build discussion$100k–$150k
Indicative range only, subject to final scope and a precise development quotation.
Whole-venture scenario$350k–$500k
Planning range for product completion, validation, evidence development and first-market preparation.
Use of funds
Dollar ranges apply the allocation to the $350k–$500k scenarioAccessible workflows, security and core data model.
$122.5k–$175kStakeholder testing and structured pilot delivery.
$87.5k–$125kMeasures, interpretation and buyer reporting.
$70k–$100kPricing, procurement and first-customer development.
$70k–$100kAllocation is illustrative and will be revised against the final build scope. Preferred capital adds healthcare knowledge, implementation access or commercialisation capability—not cash alone.
Capability
A venture coalition built around translation.
The opportunity draws together rehabilitation expertise, lived experience, product development and FASTlab’s design-and-evidence capability. Formal ownership and venture structure remain intentionally undecided.
Rehabilitation expertise
Shapes relevance, safety boundaries and workflow fit.
Survivors and carers
Shape accessibility, motivation and the realities of use at home.
FASTlab
Originates the experience design, validation pathway and Evidence Intelligence architecture.
Devika
Developing the proof of concept and informing the route to build.
Research provenance
REGAIN has emerged from research and development involving the University of Newcastle and Hunter Medical Research Institute, supported through the ARC Research Hub for Connected Sensors for Health.
- Research and development involvingUniversity of Newcastle
- Research and development involvingHunter Medical Research Institute
- Supported throughARC Research Hub for Connected Sensors for Health
Scope
This provenance establishes the research foundation of the work. It does not imply institutional endorsement of, ownership in, investment in, or commitment to the proposed commercial venture.
Structure
Designed before it is divided.
The investment case does not imply a settled ownership arrangement between REGAIN, FASTlab or future participants. Company, IP, licensing and equity arrangements must be agreed before external investment.
| Risk | De-risking action |
|---|---|
| Product adoption | Stakeholder testing before final build |
| Clinical boundary | Human-led workflow and explicit product limits |
| Buyer and pricing | Paid pilot and procurement discovery |
| Venture structure | Resolve ownership and IP before investment |
| Pathway expansion | Validate each application profile independently |
REGAIN investment proposition
Make recovery at home visible enough to support—and valuable enough to scale.
The next value-inflection point is a validated POC, a costed MVP and a credible path to the first paid deployment.